These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 30342311

  • 1. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis.
    Travaglino A, Raffone A, Saccone G, Insabato L, Mollo A, De Placido G, Zullo F.
    Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():104-110. PubMed ID: 30342311
    [Abstract] [Full Text] [Related]

  • 2. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
    Raffone A, Travaglino A, Saccone G, Mollo A, De Placido G, Insabato L, Zullo F.
    Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
    [Abstract] [Full Text] [Related]

  • 3. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: A systematic review.
    Travaglino A, Raffone A, Saccone G, Insabato L, Mollo A, De Placido G, Zullo F.
    Acta Obstet Gynecol Scand; 2019 Sep; 98(9):1086-1099. PubMed ID: 30793281
    [Abstract] [Full Text] [Related]

  • 4. PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis.
    Raffone A, Travaglino A, Saccone G, Viggiani M, Giampaolino P, Insabato L, Mollo A, De Placido G, Zullo F.
    Arch Gynecol Obstet; 2019 Jun; 299(6):1511-1524. PubMed ID: 30915635
    [Abstract] [Full Text] [Related]

  • 5. Comparative effects of different treatments based on the levonorgestrel intrauterine system in endometrial carcinoma and endometrial hyperplasia patients: a network meta-analysis.
    Tao M, Wu T, Zhou X, Du X, Ling K, Liang Z.
    Arch Gynecol Obstet; 2024 Sep; 310(3):1315-1329. PubMed ID: 38980346
    [Abstract] [Full Text] [Related]

  • 6. Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis.
    Shao F, Li Y, Zhao Y.
    Front Endocrinol (Lausanne); 2023 Sep; 14():1139858. PubMed ID: 37415671
    [Abstract] [Full Text] [Related]

  • 7. Expression of PAX2 and PTEN Correlates to Therapy Response in Endometrial Hyperplasia.
    Ørbo A, Arnes M, Lyså LM, Straume B.
    Anticancer Res; 2015 Dec; 35(12):6401-9. PubMed ID: 26637849
    [Abstract] [Full Text] [Related]

  • 8. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.
    Cholakian D, Hacker K, Fader AN, Gehrig PA, Tanner EJ.
    Gynecol Oncol; 2016 Feb; 140(2):234-8. PubMed ID: 26706662
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature.
    Baker J, Obermair A, Gebski V, Janda M.
    Gynecol Oncol; 2012 Apr; 125(1):263-70. PubMed ID: 22196499
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
    Reyes HD, Carlson MJ, Devor EJ, Zhang Y, Thiel KW, Samuelson MI, McDonald M, Yang S, Stephan JM, Savage EC, Dai D, Goodheart MJ, Leslie KK.
    Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
    [Abstract] [Full Text] [Related]

  • 16. Treatment outcomes according to various progestin treatment strategies in patients with atypical hyperplasia/endometrial intraepithelial neoplasia - Multicenter retrospective study (KGOG2033).
    Kim NK, Choi CH, Seong SJ, Lee JM, Lee B, Kim K.
    Gynecol Oncol; 2024 Apr; 183():68-73. PubMed ID: 38520881
    [Abstract] [Full Text] [Related]

  • 17. Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis.
    Raffone A, Travaglino A, Saccone G, Insabato L, Mollo A, De Placido G, Zullo F.
    Arch Gynecol Obstet; 2019 May; 299(5):1233-1242. PubMed ID: 30810881
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.